Welcome to our dedicated page for Rein Therapeutics news (Ticker: RNTX), a resource for investors and traders seeking the latest updates and insights on Rein Therapeutics stock.
Rein Therapeutics, Inc. (RNTX) is a clinical-stage biopharmaceutical company developing innovative therapies for rare pulmonary and fibrotic conditions. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical milestones, regulatory developments, and strategic initiatives.
Access timely announcements about RNTX's pipeline candidates including LTI-03 for pulmonary fibrosis and LTI-01 for pleural complications. Our curated collection features press releases on trial progress, orphan drug designations, and scientific collaborations, offering a comprehensive view of the company's advancement in addressing unmet medical needs.
Bookmark this page for verified updates on Rein Therapeutics' novel therapeutic approaches, partnership announcements, and clinical trial results. Stay informed about developments in rare disease treatment innovation through our maintained repository of official company communications and relevant industry analysis.
Rein Therapeutics (NASDAQ: RNTX) has partnered with Qureight Ltd to integrate deep-learning technology into its upcoming Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis (IPF) treatment. The collaboration follows positive Phase 1b results where LTI-03 showed promising trends in biomarkers, with five showing dose-dependent effects and four achieving statistical significance.
Qureight will provide comprehensive imaging core lab services and AI-powered analysis to evaluate LTI-03's impact on lung structure and function. Their technology will analyze lung imaging data, measure fibrotic, vascular, and airway lung compartments, and identify correlations between volumetric changes and biomarker activity. This integration aims to accelerate the trial process and provide deeper insights into LTI-03's therapeutic potential.
Rein Therapeutics (NASDAQ: RNTX), a biopharmaceutical company focused on developing first-in-class medicines for orphan pulmonary and fibrosis conditions, has announced its upcoming presentation at The Citizens Life Sciences Conference 2025.
Brian Windsor, Ph.D., who serves as President and Chief Executive Officer, will deliver the presentation on Thursday, May 8, 2025 at 12:00 p.m. EDT in New York, NY.
Interested parties can access the presentation through a live webcast at the company's investor relations website. The recording will remain available for 90 days after the event.
Rein Therapeutics (NASDAQ: RNTX) announced the acceptance of their abstract for presentation at the American Thoracic Society (ATS) 2025 International Conference in San Francisco from May 18-21, 2025. The presentation will focus on evaluating alveolar regenerative properties of Caveolin Scaffolding Peptides (CSD) in 3D alveolospheres from IPF and normal donor lung samples.
The poster presentation (P1463) is scheduled for Monday, May 19, 2025, at 11:30 AM PT/ 2:30 PM ET, as part of Session B75: Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and Fibrosis.
Rein Therapeutics (NASDAQ: RNTX) has secured two new U.S. patents (No. 12,280,088 and 12,280,089) for its lead product candidate LTI-03, a synthetic peptide administered through dry powder inhalation. The patents, issued on April 22, 2025, cover both the formulation and therapeutic applications of LTI-03.
The drug features a dual mechanism targeting alveolar epithelial cell survival and inhibition of profibrotic signaling. It is being developed to treat various respiratory conditions including:
- Interstitial lung disease (ILD)
- Idiopathic pulmonary fibrosis (IPF)
- Chronic obstructive pulmonary disease (COPD)
- Asthma and other inflammatory or fibrotic lung conditions
The company plans to initiate a Phase 2 clinical trial of LTI-03 in IPF patients during the first half of 2025.
Rein Therapeutics (NASDAQ: RNTX) has published research in Biomedicines highlighting the therapeutic potential of their LTI-2355 peptide for treating Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F).
The study demonstrates that LTI-2355, a soluble and proteolysis-resistant 13-mer CSD peptide, improved the phagocytic activity of IPF and PASC-F myeloid cells while reducing their pro-inflammatory and pro-fibrotic synthetic activity. The research was conducted using lung explant tissue from donors and patients with IPF and PASC-F.
The manuscript was authored by Rein's leadership team, including BreAnne MacKenzie, Cory M. Hogaboam, and Brian Windsor, along with researchers from Cedars-Sinai Medical Center and Duke University.
Rein Therapeutics (NASDAQ: RNTX) has reported its Q4 and full-year 2024 financial results, highlighting progress in its lead asset LTI-03 for idiopathic pulmonary fibrosis (IPF). The company announced positive topline results from Phase 1b Cohort 2 trial, with four biomarkers achieving statistical significance and five showing dose-dependent effects.
Financial highlights include:
- Cash position of $12.9M as of December 31, 2024 (down from $17.3M in 2023)
- Q4 2024 net loss of $41.0M, including $37.0M non-cash impairment charge
- Full-year R&D expenses increased to $14.2M from $4.0M in 2023
- G&A expenses rose to $13.9M from $11.4M in 2023
The company plans to initiate a Phase 2 trial for LTI-03 in IPF during first half of 2025, subject to funding. Additionally, Rein entered an exclusive option agreement with Advancium Health Network for ALRN-6924 and completed its rebranding from Aileron Therapeutics in January 2025.
Aileron Therapeutics announced its rebranding to Rein Therapeutics, reflecting its focus on developing therapies for orphan pulmonary and fibrosis indications. The company's stock will trade under the new symbol RNTX starting January 13, 2025.
The company reported positive topline data from Cohort 2 of its Phase 1b trial for LTI-03 in November 2024, showing statistical significance in four biomarkers and dose dependence in five markers for idiopathic pulmonary fibrosis (IPF) treatment. The high-dose LTI-03 (5 mg BID) demonstrated a favorable safety profile.
In 2024, Brian Windsor was appointed CEO, and the company raised $17.7 million through a stock offering. For 2025, Rein plans to initiate a Phase 2 trial for LTI-03 in IPF treatment. The company also has LTI-01, a Phase 2b-ready asset for loculated pleural effusions, which has received Orphan Drug and Fast Track Designations.
FAQ
What is the current stock price of Rein Therapeutics (RNTX)?
What is the market cap of Rein Therapeutics (RNTX)?
